Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Change in Accured Expenses (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Change in Accured Expenses data on record, last reported at -$1.6 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 150.76% year-over-year to -$1.6 million; the TTM value through Dec 2025 reached -$3.4 million, down 207.41%, while the annual FY2025 figure was -$3.4 million, 207.41% down from the prior year.
  • Change in Accured Expenses reached -$1.6 million in Q4 2025 per PLSE's latest filing, down from $427000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.2 million in Q4 2024 and bottomed at -$3.0 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $2368.4, with a median of $215000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: crashed 417.28% in 2023, then surged 454.47% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$959000.0 in 2021, then skyrocketed by 69.24% to -$295000.0 in 2022, then soared by 374.58% to $810000.0 in 2023, then surged by 295.68% to $3.2 million in 2024, then crashed by 150.76% to -$1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$1.6 million in Q4 2025, $427000.0 in Q3 2025, and $793000.0 in Q2 2025.